Go Pro
OTCMKTS:AZNCF

AstraZeneca (AZNCF) Stock Price, News & Analysis

AstraZeneca logo
$187.10 0.00 (0.00%)
As of 09/11/2026

About AstraZeneca Stock (OTCMKTS:AZNCF)

Advanced

Key Stats

Today's Range
$183.90
$187.10
50-Day Range
$187.10
$187.10
52-Week Range
$122.26
$195.00
Volume
N/A
Average Volume
1,957 shs
Market Capitalization
N/A
P/E Ratio
229.29
Dividend Yield
1.50%
Price Target
N/A
Consensus Rating
N/A

Company Overview

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms. AstraZeneca is headquartered in Cambridge, England, and operates major research centers in the United Kingdom, the United States, Sweden and China. Its commercial organization spans more than 100 countries across North and South America, Europe, Asia Pacific, the Middle East and Africa, enabling broad access to its medicines.

Under the leadership of Chief Executive Officer Pascal Soriot since 2012, AstraZeneca has pursued a strategy of innovation and external collaboration. The company has established numerous strategic alliances with academic institutions, biotechnology firms and governmental agencies to accelerate the development of new therapies. Its investments in biopharmaceutical research have yielded several breakthrough approvals in recent years, reinforcing its position in key markets and therapeutic areas.

AI Generated. May Contain Errors.

Receive AZNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZNCF Stock News Headlines

AstraZeneca, Daiichi report Enhertu benefit in advanced lung cancer
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.tc pixel
AstraZeneca wins US nod for Etcamah breast cancer combo
See More Headlines

AZNCF Stock Analysis - Frequently Asked Questions

AstraZeneca's stock was trading at $175.50 at the beginning of the year. Since then, AZNCF stock has increased by 6.6% and is now trading at $187.10.

Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:AZNCF
CIK
901832
Fax
N/A
Employees
83,500
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
229.29
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (OTCMKTS:AZNCF) was last updated on 9/14/2026 by MarketBeat.com Staff.
From Our Partners